osimertinib,lazertinib,azd9291,amivantamab
janssen,astrazeneca,yuhan corp
['sclc', 'amivantamab', 'nsclc', 'flaura', 'lazertinib', 'osimertinib']
met ihc is a strong predictive factor for the efficacy of amivantamab + lazertinib in pts with egfrmut nsclc, independently of the resistance mechanism to osimertinib. pfs 12.2/4.2mo in met+/-. might be useful if the 1st line setting becomes crowded (flaura2, mariposa ). #asco23 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.